Ultragenyx Pharmaceutical (RARE)

• Market cap: $2.77B
• 1 day: -2.61%
• 5 days: -8.13%
• 1 month: -3.33%
• 3 months: -21.69%
• 6 months: -27.57%
• Year to date: -30.23%
• 1 year: -50.91%
• 5 years: -65.17%
• 10 years: -78.16%
• Sector: Healthcare
• Industry: Biotechnology

About: Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Employees: 1,294

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

69% more call options, than puts

Call options by funds: $149M | Put options by funds: $87.7M

26% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 43

6% more capital invested

Capital invested by funds: $3.22B [Q1] → $3.42B (+$204M) [Q2]

3.52% more ownership

Funds ownership: 96.05% [Q1] → 99.56% (+3.52%) [Q2]

3% more funds holding

Funds holding: 297 [Q1] → 307 (+10) [Q2]

7% more repeat investments, than reductions

Existing positions increased: 116 | Existing positions reduced: 108

14% less funds holding in top 10

Funds holding in top 10: 7 [Q1] → 6 (-1) [Q2]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $34
• Avg. target: $76
• High target: $128

7 analyst ratings

• positive: 6 86%
• neutral: 1 14%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju	$80	Buy Reiterated	9 Sep 2025
Cantor Fitzgerald Kristen Kluska	$105	Overweight Reiterated	5 Sep 2025
Canaccord Genuity Whitney Ijem	$128	Buy Maintained	8 Aug 2025
Wedbush Laura Chico	$34	Neutral Maintained	14 Jul 2025
Morgan Stanley Jeffrey Hung	$55	Overweight Maintained	14 Jul 2025